基因工程化抗CD3单克隆抗体及其诱导免疫耐受的研究进展  

Progresses in the engineered CD3 antibodies and the immunologic tolerance induced by anti-CD3 mAbs

作　　者：吕明[1] 冯健男[1] 黎燕[1] 沈倍奋[1] 

机构地区：[1]军事医学科学院基础医学研究所,北京100850

出　　处：《免疫学杂志》2006年第z1期21-25,共5页Immunological Journal

摘　　要：CD3单克隆抗体广泛的应用于器官移植的抗排斥反应以及自身免疫病的临床治疗。该抗体的免疫原性和丝裂原活性会导致严重的毒副作用。针对抗体毒副作用进行的基因工程改造取得一定进展,目前已经有许多CD3抗体进入临床试验。抗CD3抗体可以诱导免疫抑制作用,近年来的研究发现,抗CD3抗体具有独特的诱导免疫耐受的能力,即可产生针对特异性抗原的免疫无反应性而不会发生长期的整个免疫系统的抑制状态。Anti-CD3 monoclonal antibodies are becoming more widely applicable in the treatment or prophylaxis of allograft rejection and autoimmune diseases,but the immunity and the mitogenicity of the anti-CD3 mAb could induce severe side-effects of toxicity.The genetically engineered antibodies toward the two drawbacks have made a great breakthrough,and several engineered CD3 antibodies have been used in clinical trials.The anti-CD3 mAbs can induce immunosuppression,and the recently researches revealed that the anti-CD3 mAbs could induce differential immunologic tolerance.The antiCD3 mAb could induce the antigen-specific immunosuppression,but not a long time immunosuppression of the whole immune system.

关 键 词：抗CD3抗体 丝裂原活性 基因工程 免疫耐受 

分 类 号：R392.11[医药卫生—免疫学]